The latest price target for Dermata Therapeutics (NASDAQ:DRMA) was reported by Maxim Group on August 21, 2024. The analyst firm set a price target for $6.00 expecting DRMA to rise to within 12 months (a possible 404.29% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Dermata Therapeutics (NASDAQ:DRMA) was provided by Maxim Group, and Dermata Therapeutics maintained their buy rating.

There is no last upgrade for Dermata Therapeutics

There is no last downgrade for Dermata Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dermata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dermata Therapeutics was filed on August 21, 2024 so you should expect the next rating to be made available sometime around August 21, 2025.

While ratings are subjective and will change, the latest Dermata Therapeutics (DRMA) rating was a maintained with a price target of $10.00 to $6.00. The current price Dermata Therapeutics (DRMA) is trading at is $1.19, which is out of the analyst’s predicted range.